Open AccessEverolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis
Author(s) -
Jacques Raphael,
Cory Lefebvre,
Alison L. Allan,
Joelle Helou,
Gabriel Boldt,
Theodore A. Vandenberg,
Phillip S. Blanchette
Publication year - 2020
Publication title -
targeted oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.697
H-Index - 40
eISSN - 1776-260X
pISSN - 1776-2596
DOI - 10.1007/s11523-020-00770-6
Subject(s) - medicine , everolimus , exemestane , oncology , hazard ratio , breast cancer , odds ratio , metastatic breast cancer , meta analysis , confidence interval , cancer , aromatase
Everolimus plus exemestane is approved for the treatment of hormone receptor-positive metastatic breast cancer (MBC) after progression on nonsteroidal aromatase inhibitors. The role of everolimus is less well defined in other breast cancer phenotypes and in combination with other drugs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom